High-Throughput Chemotherapeutic Drug Screening System for Gastric Cancer (Cure-GA)

Area of Science:

• Oncology
• Biotechnology
• Drug Discovery

Background:

• Three dimensional (3D) cell cultures offer advantages for drug discovery but face challenges in high-throughput screening.
• A novel high-throughput system, Cure-GA, was developed for gastric cancer drug screening.
• The system aims to discover clinically applicable anticancer drugs and predict therapeutic responses.

Purpose of the Study:

• To develop and validate a novel high-throughput 3D drug screening system for gastric cancer.
• To assess the system's ability to discover clinically applicable anticancer drugs.
• To predict patient therapeutic responses to chemotherapy.

Main Methods:

• Primary gastric cancer cells were isolated from surgical specimens.
• Patient-derived tumoroids were generated using automated 3D printing on micropillar surfaces.
• Tumoroids were exposed to chemotherapeutic agents, and cell viability was assessed via fluorescence imaging and ATP assays.

Main Results:

• The Cure-GA system achieved a 72% success rate, acquiring drug response data from 103 gastric cancer tissues within 13 days.
• Tumoroids accurately reflected the immunohistochemical, mutational, and gene expression profiles of primary tumors.
• A predictive model based on drug response data demonstrated significant differences in recurrence-free survival.

Conclusions:

• The Cure-GA platform facilitates rapid chemotherapeutic response evaluation using patient-derived tumoroids.
• This system provides valuable insights for personalized treatment strategies in gastric cancer.
• The technology has the potential to improve therapeutic outcomes for cancer patients.